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Objective. This study estimates the erythema nodosum (EN) incidence in a tuberculosis (TB) endemic setting
and evaluates the likelihood of a subsequent TB diagnosis among individuals with Mycobacterium tuberculosis
infection (MTI) with or without EN.
Design. We estimated EN incidence rates (IRs) in East Greenland in 20102011 and conducted a cohort study
following all individuals who tested positive for MTI from 1 January 2010 until 31 December 2012. A personal
identifier allowed individual follow-up in the mandatory TB register. MTI was defined by a positive interferon-
gamma release assay. TB incidence rate ratios (IRRs) among participants with or without EN were estimated
with the Cox proportional hazard model.
Results. We identified 38 EN cases corresponding to an IR of 500/100,000 inhabitants/year. All cases were
among individuals with MTI. The EN IR was 11.79 (95% CI 5.7324.27) times higher for BCG-unvaccinated
compared with BCG-vaccinated individuals. The TB IRR was 25 (95% CI 1160) within 1 month of EN
compared to individuals without EN.
Conclusion. This study documents a high EN incidence in a TB endemic region. EN occurred only in individuals
with MTI, and predominantly among BCG-unvaccinated individuals. EN was significantly associated with a
TB diagnosis within 1 month of diagnosis.
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E
rythema nodosum (EN), a septal panniculitis
presenting with tender, red nodules bilaterally on
the extremities without ulceration and scarring, is
a well-known immunologic reaction to numerous different
stimuli such as infections, drugs and malignant diseases
(1,2). The proportion of EN cases associated with Mycobac-
terium tuberculosis (Mtb) infection (MTI) was highly
debated in the early 1900s (36). While some authors
reported approximately 2030% of EN cases to be associated
with tuberculosis (TB) (3,5), others reported a potential
association in 100% of EN cases (6,7). Later, longitudinal
studies demonstrated how EN incidence decreased in a
population in parallel with a decreasing TB incidence (810).
Even though EN associated with MTI is still common in
some areas (1114), most EN cases are associated with other
diseases, and MTI is considered a rare cause (1,2,15,16).
East Greenland is a region with an extremely high TB
incidence and MTI prevalence (17,18). In 2005, a screening
of schoolchildren in the region found approximately 7%
of the children to have MTI (19). However, 7 years later,
following a TB outbreak, more than 40% of children were
infected, indicating high levels of Mtb transmission
between 2005 and 2012 (1719). Likewise, as documented
in our recently published study based on more than 4,000

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interferon-gamma release assays (IGRAs), the MTI po-
pulation prevalence in East Greenland increased drama-
tically in this period (18).
During a population-wide MTI settlement screening
in East Greenland in 2010, clinicians noted a high EN
prevalence. Almost simultaneously, the clinicians at the
local hospital began registering all incident EN cases
from the region. Within 2 years, almost 40 cases of the
characteristic skin eruptions were registered.
The aim of this study was to estimate the yearly EN
incidence in East Greenland from 2010 to 2011 and to
evaluate the likelihood of being diagnosed with TB
among individuals with MTI with or without EN.
Methods and materials
Setting
Greenland is a self-governed country within the Kingdom
of Denmark. Approximately 3,500 of Greenland’s 56,000
inhabitants populate East Greenland. The East Green-
landic population is mainly Inuit, and the majority live in
the town of Tasiilaq and five nearby settlements (18,20).
The main hospital in the region is situated in Tasiilaq.
Access to health care and treatment is free. At birth,
all Greenlanders receive a personal identification number
through the Civil Registration System (CRS), which
is subsequently used in all public registers. The CRS
number provides a unique possibility to combine data
across public registers as well as obtaining information on
age, gender, past and present places of residency and
place of birth.
Since 1955, neonatal BCG vaccination has been part of
the Greenlandic childhood vaccination programme ex-
cept for a nationwide discontinuation of the programme
from 1991 through 1996 (17,21). Therefore, individuals
born from 1991 through 1996 were considered unvacci-
nated. This assumption was validated in a previous study
(17). For BCG-vaccinated birth cohorts, the vaccination
coverage was more than 90% (22).
Case definitions
An EN case was defined as a clinical case of EN recorded
by a doctor or a nurse in one of the two registers: (a) the
20102011 local hospital register and (b) the register
from the cross-sectional settlement screening in 2010.
TB cases were identified from the mandatory Green-
landic TB notification register maintained by the National
Board of Health. The Greenlandic TB case definitions
follow WHO definitions (23,24). Hence, microbiologically
confirmed TB cases were defined by at least one sample
positive for acid-fast bacilli at microscopy, Mtb at culture
or Mtb DNA at polymerase chain reaction.
A case of MTI was defined by a positive IGRA
(Quantiferon TB Gold-in tube test, Cellestis/Qiagen)
used as recommended by the manufacturer. IGRA results
from the East Greenlandic population were obtained
either from the Central Laboratory at Queen Ingrid’s
Hospital in Nuuk or from Statens Serum Institut (SSI) in
Copenhagen. IGRAs from the Central Laboratory were
from routine TB diagnostics, contact tracing, school-
children screenings (n1,707) and population screenings
(n1,626), while IGRA from the SSI were obtained from
previous studies (n1,444) (1719). In total, IGRAs from
2,791 East Greenlanders were included in the study; of
whom, 990 individuals had at least one positive IGRA
from 1 January 2005 through before 31 December 2012.
Study design
We estimated the yearly crude EN incidence rate (IR) in
2010 and 2011 in the entire East Greenlandic population
(Npop per 1 January 20113,494) and among East
Greenlanders with MTI (n990). Furthermore, we
conducted a cohort study to assess whether individuals
with MTI and EN had a higher risk of TB as compared
with individuals with MTI without EN. East Greenlandic
inhabitants with MTI were included from the date of first
positive IGRA if this came after 1 January 2010 and
before an EN or TB diagnosis. Participants were followed
until the date of TB notification, emigration, death or
end of follow-up on 31 December 2012.
Statistical analysis
The crude EN IRs and 95% Wald confidence intervals
(CIs) were calculated from all registered EN cases diag-
nosed in 2010 and 2011 as number per 100,000 inhabitants
per year. The crude EN IRs were compared for BCG-
unvaccinated individuals (born 19911996) and BCG-
vaccinated individuals (born before 1991 or after 1996)
and compared for women and men.
In the cohort study, EN was considered as a time-
dependent covariate because included individuals could
change status from having no EN to having EN during the
study period. TB incidence rate ratios (IRRs) with 95%
CI were estimated using the Cox proportional hazard
model with age as the underlying time scale. Estimates
were adjusted for gender and year of birth in 5-year
intervals. SAS statistical software version 9.4 was used
for all analyses.
Results
Overall, 38 cases of EN were registered, of which 34 (89%)
could be validated in medical records. Among these
34 cases, 30 (88%) were described as typical examples
of EN with red, tender, often painful nodular eruptions
of the skin, while 4 were simply designated as ‘‘EN.’’ The
31 cases (91%) with detailed descriptions of the location of
the skin eruptions all reported location on the lower legs.
For 17 cases (50%), the location was further described
as being on the anterior side of the legs, and none were
described on the posterior side. Three cases (8%) had
additional eruptions on the arms, and 21 cases (66%) were
Karen Bjorn-Mortensen et al.
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reported with systemic symptoms such as fever, night
sweats, cough and weight loss at the time of EN diagnosis.
The 38 EN cases corresponded to an overall crude
IR of 544 EN cases per 100,000 inhabitants per year
(Table I), with 18 cases registered in 2010 and 20 cases
registered in 2011. The majority of EN cases were among
women (58%). Median age at the time of EN diagnosis
was 16 years (interquartile range: 1419 years).
All EN cases were diagnosed among the 990 individuals
who had tested positive for MTI. Among these, the yearly
EN IR was 1.68 (95% CI 0.883.22) times higher among
women as compared with men and 11.79 (95% CI 5.73
24.27) times higher among BCG-unvaccinated individuals.
EN and risk of TB
Of the total 990 individuals with MTI, 21% (n203)
were notified with TB. Of these, 48% (n98) were
notified in 19922009, while 52% (n105) were notified
in 20102012 (Fig. 1). Eighty-seven per cent (n176)
were pulmonary. Of the 952 individuals without EN, 19%
(n181) were notified with TB, of which 65% (n118)
were laboratory confirmed; compared to 22 (58%) noti-
fications among the 38 individuals with EN, 59% (n13)
were confirmed.
Only 739 individuals with MTI were included in the
cohort study, since the remainder had their first positive
IGRA test before 1 January 2010 or after EN or TB
diagnosis. Of these 739 individuals, 67% (n494) were
born before 1991, 17% (n129) were born between 1991
and 1996 and 16% (n116) were born after 1996. During
follow-up, 46 individuals developed TB without prior EN
as compared with 20 individuals with EN (Table II). The
majority of individuals with EN were diagnosed with TB
within the first month after EN diagnosis (n16). Thus,
among individuals with MTI, the IRR of TB within
1 month after EN was 25 (95% CI 1160) as compared
with TB without prior EN. This finding was robust for
both genders and all birth cohorts. When only including
confirmed TB cases, our estimates did not change to any
greater extent.
Discussion
This study documents a high EN incidence in East
Greenland, a TB high incidence region. From 2010 to
2011, the crude yearly IR was approximately 500 per
100,000 inhabitants. All cases were among individuals with
MTI with an 11.8 times higher IR for BCG-unvaccinated
individuals compared to BCG-vaccinated individuals.
The risk of developing TB among individuals with MTI
was significantly and dramatically increased within the
first month after EN.
EN is believed to appear in immunocompetent indivi-
duals with a strong immunologic response. EN cases
often present strong reactions to the tuberculin skin test
(TST), which represents delayed hypersensitivity reactions
(2527). Consistent with this, a recent study demonstrated
an excess cytokine response (increased production of
INFg) to Mtb antigens in EN patients (25). Additionally,
blood from EN patients was shown to exhibit an enhanced
ability to restrict mycobacterial growth in vitro.
In this study, BCG-unvaccinated individuals had the
highest risk of developing EN when infected with Mtb.
For the entire East Greenlandic population, the crude IR
of EN among these individuals was 2030 times higher
than that among BCG-vaccinated individuals. The higher
proportion of individuals with MTI among unvaccinated
individuals (Table I) could explain most of this effect.
However, when we included only individuals with MTI in
the analysis, BCG-unvaccinated individuals still had an
almost 12-fold increased EN IR, suggesting that the
immunologic response to newly acquired MTI might be
different for BCG-unvaccinated individuals as compared
Table I. Yearly crude incidence rates (IRs) with 95% confidence intervals (CIs) of registered erythema nodosum (EN) cases in East
Greenland 20102011 in the total population and among individuals with M. tuberculosis infection (MTI)
East Greenlandic population East Greenlanders with MTI
EN cases (%) Npop (% of Npop) IR (95% CI) N (% of Npop) IR (95% CI)
Entire population
Total 38 (100) 3,494 (100) 544 (396747) 990 (28) 1,919 (1,3962,638)
Gender
Women 23 (61) 1,678 (48) 685 (4551,031) 472 (28) 2,436 (1,6193,666)
Men 15 (39) 1,816 (52) 413 (248685) 518 (29) 1,448 (8722,401)
Year of birth
Before 1991 (BCG-vaccinated) 6 (16) 2,120 (61) 142 (64314) 660 (31) 455 (2041,012)
19911996 (BCG-unvaccinated) 28 (74) 350 (10) 4,000 (2,7625,793) 190 (54) 7,368 (5,08810,672)
After 1996 (BCG-vaccinated) 4 (10) 1,024 (29) 195 (73520) 140 (14) 1,429 (5363,806)
IRs calculated as the number of EN cases per 100,000 inhabitants per year. EN was diagnosed in daily clinical routine 20102011 or at a
TB screening in 2010. Npop is the number of inhabitants per 1 January 2011. MTI was defined by a positive interferon-gamma release
assay before the end of 2012.
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to BCG-vaccinated individuals. The increased risk of EN
in BCG-unvaccinated East Greenlandic individuals did
not imply an enhanced ability to restrict mycobacterial
growth, since it has been documented that the same
individuals had a higher risk of MTI and TB (17).
However, it does appear that the immune response to
newly acquired MTI differs according to BCG vac-
cination status. Although this is an interesting observa-
tion, it is beyond the scope of this paper to explore this
topic further.
Several studies suggest that EN be considered as a
symptom of underlying TB rather than exclusively a
response to newly acquired MTI (14,28,29). In this study,
approximately 50% of individuals with MTI and EN
were subsequently diagnosed with TB; the majority were
diagnosed within 1 month after EN with a 25-fold in-
creased risk during this time period as compared to
individuals with MTI and no EN. Thus, in this study, the
risk of TB was very high among individuals with MTI and
EN, suggesting EN as either a strong predictor of TB or an
early symptom of TB. Either way, EN can be used to
identify individuals with MTI with the highest likelihood
of a subsequent TB diagnosis, who should be examined
carefully and followed closely. This was already proposed
Fig. 1. The number of notified tuberculosis (TB) cases (n203)
from 1992 to 2012 among the 990 East Greenlanders with
Mycobacterium tuberculosis infection (MTI).
Table II. Incidence rate ratios (IRRs) of tuberculosis (TB) among 739 East Greenlanders with a first positive interferon-gamma release
assay (IGRA) after 1 January 2010 and before erythema nodosum (EN) or TB diagnosis
All notified TB cases Confirmed TB cases
Person years Cases IRR (95% CI) Person years Cases IRR (95% CI)
All
No prior EN 1,032 46 1 (ref) 1,086 27 1 (ref)
030 days after EN 3.6 16 25 (1160) 4.9 9 13 (4.437)
30 days after EN 39 4 0.8 (0.32.5) 55 3 0.7 (0.22.4)
Women
No prior EN 498 19 1 (ref) 516 13 1 (ref)
030 days after EN 2.2 9 44 (13153) 3.1 5 13 (2.960)
30 days after EN 23 3 1.2 (0.34.1) 32 3 1.3 (0.35.0)
Men
No prior EN 534 27 1 (ref) 571 14 1 (ref)
030 days after EN 1.4 7 15 (4.349) 1.7 4 13 (2.759)
30 days after EN 16 1 0.4 (0.13.6) 23 0 NA
Born before 1991 (BCG-vaccinated)
No prior EN 743 27 1 (ref) 779 16 1 (ref)
030 days after EN 0.7 1 7.7 (0.696) 1,0 0 NA
30 days after EN 7.7 1 2.6 (0.322) 12 1 3,0 (0.326)
19911996 (BCG-unvaccinated)
No prior EN 113 19 1 (ref) 128 11 1 (ref)
030 days after EN 2.3 15 37 (1590) 3.2 9 40 (12135)
30 days after EN 22 2 0.5 (0.12.2) 34 1 0.3 (0.042.4)
After 1996 (BCG-vaccinated)
No prior EN 176 0 1 (ref) 179 0 1 (ref)
030 days after EN 0.6 0 NA 0.6 0 NA
30 days after EN 9.9 1 NA 9.9 1 NA
Individuals without a diagnosis of EN compared to individuals diagnosed with TB less than 30 days after EN or more than 30 days after
EN. IRRs were estimated with Cox proportional hazard model with age as the underlying time scale. Estimates were adjusted for gender
and year of birth in 5-year intervals.
Karen Bjorn-Mortensen et al.
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in 1938 by Wallgreen who suggested that EN be considered
as a ‘‘favourable syndrome’’ which aids early diagnosis and
treatment of pulmonary TB (28). Our findings, in accor-
dance with earlier studies, led to an interesting discussion
on whether individuals with MTI and EN should be
treated for TB or with preventive monotherapy. WHO
guidelines stress the need to exclude TB before prescribing
preventive monotherapy in order to avoid the development
of drug resistance (30). In accordance with our findings,
it seems highly relevant to consider screening for MTI and
TB in individuals presenting with EN. However, in hard to
reach populations with limited possibility of continuous
monitoring for TB symptoms, it might be wise to initiate
TB treatment in patients with MTI and EN.
The major strength of this study is the population-based
design, the well-maintained registers and the unique pos-
sibility of data linkage on a personal level. However, some
potential biases can be discussed. We assumed that all
individuals born before or after the period 19911996
were BCG-vaccinated at birth. When including the entire
East Greenlandic population, not regarding place of birth,
some individuals in the assumed BCG-vaccinated cohorts
might be unvaccinated. However, as immigration to East
Greenland is low, we consider potential misclassification
of BCG-vaccination status to be of minor importance. No
biopsies were available for histopathological validation of
EN diagnoses. However, other causes such as HIV infec-
tion are almost non-existent in the region; malnutrition
is rare and type 2 diabetes is unlikely to be relevant in our
EN cases, who had a median age of 16 (31). In addition,
almost all EN cases were validated in medical records, and
for a majority of cases, the description of EN lesions was
very detailed. Thus, we believe EN diagnoses to be correct.
The EN IR in this study represents a minimum incidence
only, since only individualswith severe or painful eruptions
were likely to have consulted the health care system. In
addition, EN cases were not systematically registered in the
remote town of Ittoqqortoormiit, which would potentially
result in misclassification of EN cases as non-EN cases.
On the contrary, clinicians in East Greenland could have
been sensitized to make an EN diagnosis after the re-
cognition of a TB outbreak in the region. However, the
data in the hospital register were collected prospectively
as symptomatic individuals presented themselves at the
local hospital and not by any systematic screening effort.
Likewise, the clinician treating individuals with EN could
have been more prone to do a closer TB examination and
be more inclined to diagnose TB, which might lead to
observer bias. However, when only including confirmed
TB cases in our analysis, the association between EN
and subsequent TB was the same as when we included all
notified TB cases. Due to the small number of cases in our
study, stratifying the findings would have been limited.
However, both methods showed a significant increase
in IRR of TB within 1 month of EN which reassures us
of the close relationship between EN and a subsequent TB
diagnosis. Hence, we chose to adjust the findings rather
than stratify.
This study reminds us that in a TB high incidence
setting, EN among individuals with MTI is common, and
MTI should not be considered a rare cause of EN as de-
scribed in recent literature (1,2,15,16). Many publications
on EN aetiology are from countries where TB is rare and
where MTI is not prevalent (3235), which might explain
the difference in EN incidence and aetiology in different
settings. Indeed, in older reports, EN is often described as a
clear indication of MTI (6). EN was believed to appear
approximately at the same time as tuberculin reactivity and
is therefore considered as a symptom of newly acquired
infection (7). In East Greenland, this fits well with the
timeframe, since the unusually high number of EN cases
was reported approximately at the same time as the TB
incidence started to increase and new Mtb transmission
was occurring (18).
In conclusion, this study documents a high incidence
of EN in a TB high incidence setting. EN occurred only
among individuals with MTI and predominantly among
BCG-unvaccinated individuals. Since the diagnosis of
EN was significantly associated with the diagnosis of TB
within the first month, this study strongly suggests that
individuals with MTI presenting with EN have an in-
creased likelihood of a subsequent TB diagnosis.
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